New imaging reveals how cyclosporine eye drops calm dry eye inflammation

NCT ID NCT06898853

Recruiting now Knowledge-focused Sponsor: The University of New South Wales Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study will test whether 0.1% cyclosporine A eye drops can change the number and behavior of immune cells on the eye's surface in people with dry eye disease. Researchers will use a special microscope to watch these cells move over 12 weeks and compare the drops to a lubricating eye drop. The goal is to understand how cyclosporine A reduces inflammation, which could improve future treatments.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: 0.1% cyclosporine A eye drops
What this could lead to: If successful, this could help doctors understand exactly how cyclosporine A calms the immune response in dry eye, leading to better-targeted treatments.
What could go wrong: This is a small, early-stage study (60 people) that focuses on measuring immune cells, not on curing symptoms. The results may not apply to all dry eye patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for DRY EYE DISEASE (DED) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

dry eye syndrome

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

DRY EYE DISEASE (DED)

Contacts and locations

Locations

School of Optometry and Vision Science
RECRUITING

Sydney, New South Wales, 2033, Australia

More trials for these conditions

Other studies related to the condition(s) this trial covers.